摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

chloromethyl (S)-((1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl)(8-chloro-3-cyano-4-(neopentylamino)quinolin-6-yl)carbamate

中文名称
——
中文别名
——
英文名称
chloromethyl (S)-((1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl)(8-chloro-3-cyano-4-(neopentylamino)quinolin-6-yl)carbamate
英文别名
chloromethyl N-[(S)-[1-(1-bicyclo[1.1.1]pentanyl)triazol-4-yl]-(2-methyl-1-oxoisoquinolin-5-yl)methyl]-N-[8-chloro-3-cyano-4-(2,2-dimethylpropylamino)quinolin-6-yl]carbamate
chloromethyl (S)-((1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl)(8-chloro-3-cyano-4-(neopentylamino)quinolin-6-yl)carbamate化学式
CAS
——
化学式
C35H34Cl2N8O3
mdl
——
分子量
685.613
InChiKey
NMHMOWGUMGFOHJ-ILNPBIMBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.5
  • 重原子数:
    48
  • 可旋转键数:
    10
  • 环数:
    8.0
  • sp3杂化的碳原子比例:
    0.37
  • 拓扑面积:
    129
  • 氢给体数:
    1
  • 氢受体数:
    8

反应信息

点击查看最新优质反应信息

文献信息

  • Cot modulators and methods of use thereof
    申请人:Gilead Sciences, Inc.
    公开号:US10947259B2
    公开(公告)日:2021-03-16
    The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
    本公开一般涉及Cot(癌症大阪甲状腺)的调节剂及其使用和制造方法。
  • COT MODULATORS AND METHODS OF USE THEREOF
    申请人:Gilead Sciences, Inc.
    公开号:US20210061831A1
    公开(公告)日:2021-03-04
    The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
  • [EN] SOLID FORMS OF A COMPOUND FOR MODULATING COT<br/>[FR] FORMES SOLIDES D'UN COMPOSÉ POUR MODULATION DE COT
    申请人:[en]GILEAD SCIENCES, INC.
    公开号:WO2023220123A1
    公开(公告)日:2023-11-16
    Disclosed herein are solid forms of a compound useful for modulating Cot. The disclosure also relates to pharmaceutical compositions containing one or more of the solid forms disclosed herein, as well as methods of using the solid forms in the treatment of conditions mediated by Cot. The disclosure also relates to methods for obtaining such solid forms.
查看更多